drugset / Trial / NCT06084780
Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)
NaSingle-groupOpen-labelTreatment
Summary
The goal of this prospective phase 2 study is to assess the efficacy and safety of intestinal or multivisceral transplantation for participants with PMP not amenable to other curative-intent treatments. Participants will undergo intestinal/multivisceral transplantation. Participants will be followed for 12 months to assess efficacy and safety.
Timeline
- Start
- 2026-08
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Alemtuzumab | Monoclonal antibody | 30 mg | Intravenous |
| Background | Sirolimus | Small molecule | 2 mg | — |
| Background | Tacrolimus | Small molecule | 0.05 mg/kg | — |